Business
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care,
About this update from Tempus Ai, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nTempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company’s use of AI-driven solutions to advance precision oncology.\n\n\n“At ASCO 2025, we are proud to showcase a diverse portfolio of studies that highlight how our cutting-edge technologies, including tumor-naive and tumor-informed MRD monitoring, whole genomic sequencing for hematologic malignancies, and multi-omic biomarker profiling, are providing clinicians and researchers with actionable insights to personalize treatment and improve outcomes for patients,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “We are excited to share these advancements and collaborate with the oncology community to shape the future of precision medicine.”\n\n\nResearch highlights include:\n\n\n\nOral Presentation (1506): A technology-enabled clinical trial program’s impact on patient screening and trial enrollment in 2024\n\n\nDate/Time: Monday, June 2 from 3:00 PM–6:00 PM CDT\n\n\n\nOverview: The TIME network utilized algorithmic screening technology combined with nurse match review to screen over 1.28 million patients for clinical trials in 2024, resulting in 573 total consents - an average of 1.57 consents per day. The network’s programmatic screening at scale, Tempus nurse review, and rapid activation processes helps increase patient access to trials.\n\n\n\n\n\n\n\nPoster Presentation (213/3544): Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment\n\n\nDate/Time: Saturday, May 31 from 9:00 AM–12:00 PM CDT\n\n\n\nOverview: Tempus xM, a tumor-naive test, serves as a prognostic tool for monitoring disease recurrence in resected liver-limited mCRC patients treated with upfront systemic therapy. xM demonstrates strong performance in predicting clinical recurrence and relapse-free survival following surgery.\n\n\n\n\n\n\n\nPoster Presentation (499/11160): Evaluation of large la...